Chiauranib
Phase 3Small molecule
Chiauranib is one of 135 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.
3
Indications
16
Total Trials
4
Active Trials
134
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
232 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Gemzar
Johnson & JohnsonPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Femara
NovartisPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rubraca
Bristol-Myers SquibbPhase 3
Trodelvy
GileadPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Nolvadex
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer3 trials
Pancreatic Ductal Adenocarcinoma2 trials
Lymphoma2 trials
Chiauranib2 trials
6 more indications
Small Cell Lung Cancer1 trial
Lung Cancer1 trial
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Chiauranib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CChipscreen Biosciences, Ltd.